Genta Inc. About
Genta Inc: Genta’s
pipeline is anchored by two key programs: RNA/DNA Medicines (which include
products that employ Antisense, RNA interference and Decoys ); and Small Molecules
. The products from each of these platforms address significant unmet medical
needs. The Company’s lead drug from its RNA/DNA Medicines program is Genasense®
(oblimersen sodium). Genasense is currently in late-stage clinical
trials for the treatment of melanoma,
multiple myeloma, chronic lymphocytic
leukemia, non-small cell lung
cancer, small cell lung cancer and prostate cancer. In December 2003,
Genta submitted a New Drug Application (NDA) for Genasense plus chemotherapy for
the treatment of patients with advanced malignant melanoma to the U.S. Food and
Drug Administration. The Company’s leading drug from its Small Molecules program
is Ganite® (gallium nitrate injection).
Key
Statistics for Genta
Genta
Incorporated is a biopharmaceutical company focused on the identification, development
and commercialization of drugs for the treatment of patients with cancer
More on Genta Inc.
Basic
Chart for Genta
Analyst
Opinion
Analysts
Estimates